Gene/Protein
Disease
Symptom
Drug
Enzyme
Compound
Pivot Concepts:
Gene/Protein
Disease
Symptom
Drug
Enzyme
Compound
Target Concepts:
Gene/Protein
Disease
Symptom
Drug
Enzyme
Compound
Query: UMLS:C0345904 (
liver cancer
)
15,188
document(s) hit in 31,850,051 MEDLINE articles (0.00 seconds)
As
2
O
3
-loaded nanoparticles (NPs) based on poly (lactic-co-glycolic acid) (PLGA) were prepared by double emulsion-solvent evaporation method. Then
Lactose
acid (LA) and/or PEG were modified onto the NPs by chemical covalent coupling through -NH
2
and -COOH. The FTIR results showed that LA and PEG could be successfully modified onto the surface of the NPs. All the As
2
O
3
-loaded PLGA NPs (As
2
O
3
@PLGA NPs) presented suitable physical stability, favorable size, and spherical shape. The in vitro release rate of As
2
O
3
from the NPs depended on the surface of the NPs. As expected, the As
2
O
3
@PLGA-PEG/LA NPs showed a moderate release rate, the highest anticancer effects and cellular internalization against SMMC-7721 cell line. The PLGA-PEG/LA NPs could represent an effective nano-size delivery system of As
2
O
3
for treatment of
liver cancer
.
...
PMID:Effects of surface modification of As
2
O
3
-loaded PLGA nanoparticles on its anti-liver cancer ability: An in vitro and in vivo study. 2979 91
